- Home
- CERO vs PRPO Comparison
CERO vs PRPO Comparison
Compare CERO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- PRPO
- Stock Information
- Founded
- CERO 2017
- PRPO N/A
- Country
- CERO United States
- PRPO United States
- Employees
- CERO N/A
- PRPO N/A
- Industry
- CERO
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- CERO
- PRPO Industrials
- Exchange
- CERO Nasdaq
- PRPO Nasdaq
- Market Cap
- CERO 3.5M
- PRPO N/A
- IPO Year
- CERO N/A
- PRPO N/A
- Fundamental
- Price
- CERO $9.41
- PRPO $12.05
- Analyst Decision
- CERO Strong Buy
- PRPO
- Analyst Count
- CERO 2
- PRPO 0
- Target Price
- CERO $45.00
- PRPO N/A
- AVG Volume (30 Days)
- CERO 3.3M
- PRPO 9.7K
- Earning Date
- CERO 08-13-2025
- PRPO 08-12-2025
- Dividend Yield
- CERO N/A
- PRPO N/A
- EPS Growth
- CERO N/A
- PRPO N/A
- EPS
- CERO N/A
- PRPO N/A
- Revenue
- CERO N/A
- PRPO $20,029,000.00
- Revenue This Year
- CERO N/A
- PRPO N/A
- Revenue Next Year
- CERO N/A
- PRPO N/A
- P/E Ratio
- CERO N/A
- PRPO N/A
- Revenue Growth
- CERO N/A
- PRPO 26.67
- 52 Week Low
- CERO $6.71
- PRPO $3.90
- 52 Week High
- CERO $895.40
- PRPO $12.45
- Technical
- Relative Strength Index (RSI)
- CERO 47.59
- PRPO 65.45
- Support Level
- CERO $9.10
- PRPO $10.60
- Resistance Level
- CERO $9.73
- PRPO $11.70
- Average True Range (ATR)
- CERO 2.72
- PRPO 0.60
- MACD
- CERO 0.09
- PRPO -0.08
- Stochastic Oscillator
- CERO 13.44
- PRPO 79.57
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.